Comment re: "Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention" and "aberrant crypt foci in the adenoma prevention with celecoxib trial"

Cancer Prevention Research

Volumn 1, Issue 3, 2008, Pages 215-216

  Stevens, Richard G ^a   Pretlow, Theresa P ^b   Hurlstone, D Paul ^c   Giardina, Charles ^d   Rosenberg, Daniel W ^a  

^a UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^b CASE WESTERN RESERVE UNIVERSITY   (United States)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

^d UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; CELECOXIB; PYRAZOLE DERIVATIVE; SULFONAMIDE;

ADENOMA; CANCER DIAGNOSIS; CHEMOPROPHYLAXIS; CLINICAL TRIAL; COLORECTAL TUMOR; CONSENSUS; EVALUATION; HUMAN; INTESTINE MUCOSA; METHODOLOGY; NOTE; PATHOLOGY; PRECANCER;

ADENOMA; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CHEMOPREVENTION; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; CONSENSUS; EARLY DETECTION OF CANCER; HUMANS; INTESTINAL MUCOSA; PRECANCEROUS CONDITIONS; PYRAZOLES; SULFONAMIDES;

EID: 58349116592     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0094     Document Type: Letter

References (10)

1. Lance P, Hamilton SR. Sporadic aberrant crypt foci are not a surrogate endpoint for colorectal adenoma prevention. Cancer Prev Res 2008;1:4-8 Available from: http://cancerpreventionresearch.aacrjournals.org/cgi/reprint/1/1/4.
2. Cho NL, Redston M, Zauber AG, et al. Aberrant crypt foci in the Adenoma Prevention with Celecoxib trial. Cancer Prev Res 2008;1:21-31 Available from: http://cancerpreventionresearch.aacrjournals.org/cgi/reprint/1/1/21.
3. Stevens RG, Swede H, Rosenberg DW. Epidemiology of colonic aberrant crypt foci: review and analysis of existing studies. Cancer Lett 2007;252: 171-83.
4. Bird RP. Observation and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings. Cancer Lett 1987;37: 147-51.
5. Pretlow TP, Barrow BJ, Ashton WS, et al. Aberrant crypts: putative preneoplastic foci in human colonic mucosa. Cancer Res 1991;51: 1564-7.
6. Siu I-M, Robinson DR, Schwartz S, et al. The identification of monoclonality in human aberrant crypt foci. Cancer Res 1999;59:63-6.
7. Suzuki H, Watkins DN, Jair K-W, et al. Epigenetic inactivation of SFRP genes allows constitutive Wnt signaling in colorectal cancer. Nat Genet 2004;36: 417-22.
8. Rosenberg DW, Yang S, Pleau DC, et al. Mutations in BRAF and KRAS differentially distinguish serrated versus non-serrated hyperplastic aberrant crypt foci in humans. Cancer Res 2007;67:3551-4.
9. Corpet DE, Pierre F. How good are rodent models of carcinogenesis in predicting efficacy in humans? A systematic review and meta-analysis of colon chemoprevention in rats, mice, and men. Eur J Cancer 2005;41:1911-22.
10. Gupta AK, Pretlow TP, Schoen RE. Aberrant crypt foci: what we know and what we need to know. Clin Gastroenterol Hepatol 2007;5:526-33.